Solo Metadatos

Prevalence of HPV-DNA and anti-HPV antibodies in women from girardot, Colombia

dc.creatorLeon, Sandraspa
dc.creatorSánchez, Ricardospa
dc.creatorPatarroyo, Manuel A.
dc.creatorCamargo, Milenaspa
dc.creatorMejia, Adrianospa
dc.creatorUrquiza, Mauriciospa
dc.creatorPatarroyo, Manuel Espa
dc.description.abstractObjective: To assess the frequency of HPV-DNA detection, human papillomavirus (HPV) seropositivity, presence of cervical lesions, and its relationship with certain socio-demographic factors in women from Girardot, Colombia from 2006 to 2007. Methods: Nine hundred fifty-three women attending their regular Pap smear control voluntarily provided cervical cells and blood samples for HPV-DNA analysis and ELISA detection of anti-L1 peptides and virus-like particles (VLPs) antibodies after answering a questionnaire regarding sexual behaviors, number of births, smoking habits, and socio-demographic background. Results: Twenty-six of the 953 women being examined (2.73%) presented cervical cell abnormalities. A frequency of 36.62% (95% CI: 33.52%–39.7%) HPV seropositivity was detected with peptide 18301, 35.36% (95% CI: 32.3%–38.4%) with 18283, and 32.95% (95% CI: 29.9%–36%) with 18294, whereas VLPs detected a 43% seropositivity (95% CI: 39.8%– 46.2%). Antibody frequency found with all peptides was significantly higher in women having cervical abnormalities (atypical squamous cells of undetermined significance and high-grade squamous intraephitelial lesions) compared with those having normal cytologies. Peptide 18283 reported a significantly higher seropositivity (35.71%) in women 44 years old, whereas peptides 18301 and 18294 evidenced a significantly lower seropositivity in those who had never given birth. HR-HPV-DNA was detected in 157 (20.50%) of 766 cervical samples amplifying positively for the -globin housekeeping gene. Conclusion: Peptides 18283, 18294, and 18301 were more specific and more sensitive than VLPs for detecting women with HR-HPV-DNA positive cervical lesions. Therefore, they could be useful in the design of a serological test for detecting HR-HPV-infected women having cervical lesions at a risk of progressing to cervical cancer.eng
dc.identifier.issnISSN: 0148-5717
dc.identifier.issnEISSN: 1537-4521
dc.publisherAmerican Sexually Transmitted Diseases Associationspa
dc.relation.citationIssueNo. 5
dc.relation.citationTitleSexually Transmitted Diseases, Journal of the American Venereal Disease Association
dc.relation.citationVolumeVol. 35
dc.relation.ispartofSexually Transmitted Diseases, Journal of the American Venereal Disease Association, ISSN: 0148-5717;EISSN: 1537-4521, Vol.35, No.5 (May 2009); pp. 290-296spa
dc.rights.accesoAbierto (Texto Completo)spa
dc.sourceSexually Transmitted Diseases, Journal of the American Venereal Disease Associationspa
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subject.keywordPapilloma virus infections complicationsspa
dc.subject.keywordSeroepidemiologic studiesspa
dc.subject.keywordUterine cervical neoplasms / epidemiologyspa
dc.titlePrevalence of HPV-DNA and anti-HPV antibodies in women from girardot, Colombiaspa
dc.title.TranslatedTitlePrevalencia de VPH-ADN y anticuerpos anti-VPH en mujeres de girardot, Colombiaspa